Factors promoting tumor angiogenesis

Cancer Investigation

Volumn 17, Issue 8, 1999, Pages 594-623

  Beckner, Marie E ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; COLLAGEN; FIBRIN; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; HYALURONIC ACID; INTEGRIN; INTERLEUKIN 8; LAMININ; METALLOPROTEINASE; MIDKINE; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; PLEIOTROPHIN; SCATTER FACTOR; SERINE PROTEINASE; SOMATOMEDIN; TENASCIN; THROMBOPLASTIN; THYMIDINE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; GROWTH REGULATION; HUMAN; MACROPHAGE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0032747902     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032845     Document Type: Article

References (466)

1. Goldman E: The growth of malignant disease in man and the lower animals. Lancet 2:1236-1240, 1907.
2. Lewis WH: The vascular patterns of tumors. Johns Hopkins Hosp Bull 41:156-171, 1927.
3. Ide AG, Baker NH, Warren SL: Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol Radiother 42:891-899, 1939.
4. Algire GH, Chalkley Hw, Legallais FY, et al: Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6:73-85, 1945.
5. Bierman HR, Kelly KH, Dod KS, et al: Studies on the blood supply of tumors in man. I. Fluorescence of cutaneous lesions. J Natl Cancer Inst 11:877-887, 1950.
6. Burrows H: The permeability of the blood vessels in and around grafted Jensen rat sarcoma. Am J Cancer 18:383-387, 1939.
7. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971.
8. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46:467-473, 1986.
9. Folkman J, Klagsburn M: Angiogenic factors. Science 235:442-447, 1987.
10. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990.
11. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71, 1992.
12. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996.
13. D'Amore PA, Shima DT: Tumor angiogenesis: a physiological process or genetically determined? Cancer Met Rev 15:205-212, 1996.
14. Liotta LA, Kleinerman J, Saidel GM: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34:997-1004, 1974.
15. Folkman J: Angiogenesis and breast cancer. J Clin Oncol 12: 441-443, 1994.
16. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.
17. Macchiarini P, Fontanini G, Hardin MJ, et al: Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 340:145-146, 1992.
18. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409, 1993.
19. Tanigawa N, Matsumura M, Amaya H, et al: Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 79:220-225, 1997.
20. Dickinson AJ, Fox SB, Persad J, et al: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74:762-766, 1994.
21. Jaeger TM, Weidner N, Chew K, et al: Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 154:69-71, 1995.
22. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: a new significant independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992.
23. Horak ER, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.
24. Srivastava A, Laidler P, Davies RP, et al: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. Am J Pathol 133:419-423, 1988.
25. Wakui S. Furusato M, Itoh T, et al: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 168:257-262, 1992.
26. Vesalainen S, Lipponen P, Talja M, et al: Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res 14:709-714, 1994.
27. Takahashi Y, Kitadai Y, Bucana CD, et al: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964-3968, 1995.
28. Tanigawa N, Amaya H, Matsumura M, et al: Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 56:2671-2676, 1996.
29. Leek RD, Lewis CE, Whitehouse R, et al: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629, 1996.
30. Meininger CJ, Zetter BR: Mast cells and angiogenesis. Semin Cancer Biol 3:73-79, 1992.
31. Polverini PJ, Leibovich SJ: Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 51:635-642, 1984.
32. Xiong M, Elson G, Legarda D, et al: Production of vascular endothelial growth factor by murine macrophages regulation by hypoxia, lactate, and inducible nitric oxide synthase pathway. Am J Pathol 153:587-598, 1998.
33. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36:127-137, 1995.
34. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995.
35. Neufeld G, Tessler S, Gitay-Goren H, et al: Vascular endothelial growth factor and its receptors Prog Growth Factor Res 5:89-97, 1994.
36. Pepper MS, Mandriota SJ, Vassalli J-D, et al: Angiogenesis-regulating cytokines: activities and interactions. In: Attempts to Understand Metastasis Formation II, Vol. 213/II, edited by U Gunthert, W Birchmeier, New York, Berlin Springer Verlag, 1996, pp. 31-67.
37. Brown JM, Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416, 1998.
38. Takahashi Y, Cleary KR, Mai M, et al: Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 2: 1679-1684, 1996.
39. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993.
40. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858, 1989.
41. Berse B, Brown LF, Van De Water L, et al: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211-220, 1992.
42. Taichman NS, Cruchley AT, Fletcher LM, et al: Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis. Lab Invest 78:869-875, 1998.
43. Houck KA, Ferrara N, Winer J, et al: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814, 1991.
44. Tischer E, Mitchell R, Hartman T, et al: The human gene for vascular endothelial growth factor. J Biol Chem 266:11947-11954, 1991.
45. 165 via its exon 7-encoded domain. J Biol Chem 271:5761-5767, 1996.
46. Minchenko A, Bauer T, Salceda S, et al: Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71:374-379, 1994.
47. Shweiki D, Neeman M, Itin A, et al: Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92:768-772, 1995.
48. Shweiki D, Itin A, Soffer D, et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992.
49. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848, 1992.
50. Forsythe JA, Jiang B-H, Iyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613, 1996.
51. Ikeda E, Achen MG, Breier G, et al: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270: 19761-19766, 1995.
52. Levy AP, Levy NS, Goldberg MA: Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271:2746-2753, 1996.
53. Liu Y, Cox SR, Morita T, et al: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Circ Res 77:638-643, 1995.
54. Mukhopadhyay D, Tsiokas L, Zhou X-M, et al: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375:577-581, 1995.
55. Jiang B-H, Agani F, Passaniti A, et al: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIG-1 in tumor progression. Cancer Res 57: 5328-5335, 1997.
56. Koura AN, Liu W, Kitadai Y, et al: Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 56:3891-3894, 1996.
57. Rak J, Mitsuhashi Y, Bayko L, et al: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575-4580, 1995.
58. Grugel S, Finkenzeller G, Weindel K, et al: Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270:25915-25919, 1995.
59. Larcher F, Robles AI, Duran H, et al: Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56:5391-5396, 1996.
60. Volpert OV, Dameron KM, Bouck N:Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14:1495-1502, 1997.
61. Kieser A, Weich HA, Brandner G. et al: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969, 1994.
62. Siemeister G, Weindel K, Mohrs K, et al: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299-2301, 1996.
63. Finkenzeller G, Marme D, Weich HA, et al: Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res 52:4821-4823, 1992.
64. Finkenzeller G, Sparacio A, Technau A, et al: Spl recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15:669-676, 1997.
65. Detmar M, Yeo K-T, Nagy JA, et al: Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 105:44-50, 1995.
66. Ben-Av P, Crofford LJ, Wilder RL, et al: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 372:83-87, 1995.
67. Dolecki GJ, Connolly DT: Effects of a variety of cytokines and inducing agents on vascular permeability factor mRNA levels in U937 cells. Biochem Biophys Res Commun 180:572-578, 1991.
68. Tsai J-C, Goldman CK, Gillespie GY: Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 82:864-873, 1995.
69. Cohen T, Nahari D, Cerem LW, et al: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736-741, 1996.
70. Akagi Y, Liu W, Zebrowski B, et al: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58:4008-4014, 1998.
71. Silvagno F, Follenzi A, Arese M, et al: In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler Thromb Vasc Biol 15:1857-1865, 1995.
72. Hyder SM, Stancel GM, Chiappetta C, et al: Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56:3954-3960, 1996.
73. Cullinan-Bove K, Koos RD: Vascular endothelial growth factor/ vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133:829-837, 1993.
74. Banerjee SK, Sarkar DK, De A, et al: Effect of estrogen on expression of vascular endothelial growth factor (VEGF) during estrogen-induced pituitary angiogenesis in Rat. Proc Am Assoc Cancer Res 37:222, 1996.
75. Joseph IBJK, Isaacs JT: Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 57:1054-1057, 1997.
76. Hyder SM, Murthy L, Stancel GM: Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58:392-395, 1998.
77. Kuroki M, Beerepoot LV, Voest EE, et al: Regulation of VEGF mRNA expression by reactive oxygen intermediates. Invest Ophthalmol Visual Sci 36:S895, 1995.
78. Plate KH, Breier G, Risau W: Molecular mechanisms of development and tumor angiogenesis. Brain Pathol 4:207-218, 1994.
79. Leung DW, Cachianes G, Kuang W-J, et al: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
80. Pepper MS, Ferrara N, Orci L, et al: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902-906, 1991.
81. Unemori EN, Ferrara N, Bauer EA, et al: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153:557-562, 1992.
82. Alon T, Hemo I, Itin A, et al: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024-1028, 1995.
83. Nor JE, Christensen J, Mooney DJ, et al: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced cell survival and induction of Bcl-2 expression. Am J Pathol 154:375-384, 1999.
84. Ku DD, Zaleski JK, Liu S, et al: Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 265:H586-H592, 1993.
85. Dvorak HF, Orenstein NS, Carvalho AC, et al: Induction of fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 122: 166-174, 1979.
86. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983.
87. Dvorak HF, Detmar M, Claffey KP, et al: Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107:233-235, 1995.
88. Yeo K-T, Wang HH, Nagy JA, et al: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53:2912-2918, 1993.
89. Nagy JA, Masse EM, Herzberg KT, et al: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55:360-368, 1995.
90. Luo JC, Yamaguchi S, Shinkai A, et al: Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res 58:2652-2660, 1998.
91. Nguyen LS, Villablanca AC, Rutledge JC: Substance P increases microvascular permeability via nitric oxide-mediated convective pathways. Am J Physiol 268:R1060-R1068, 1995.
92. Laszlo F, Whittle BJR, Evans SM, et al: Association of microvascular leakage with induction of nitric oxide synthase: effects of nitric oxide synthase inhibitors in various organs. Eur J Pharmacol 283:47-53, 1995.
93. van der Zee R, Murohara T, Luo Z, et al: Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 95:1030-1037, 1997.
94. Roberts WG, Palade GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108:2369-2379, 1995.
95. Yeo T-K, Dvorak HF: Tumor stroma. In: Diagnostic Immunopathology, edited by RB Colvin, AK Bhan, RT McCluskey, New York: Raven Press, 1995, pp. 685-697.
96. Yoshiji H, Harris SR, Thorgeirsson UP: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57:3924-3928, 1997.
97. Terman BI, Carrion M, Kovacs E, et al: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677-1683, 1991.
98. Shibuya M, Yamaguchi S, Yamane A, et al: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to fms family. Oncogene 5:519-524, 1990.
99. De Vries C, Escobedo JA, Ueno H, et al: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991, 1992.
100. Merenmies J, Parada LF, Henkemeyer M: Receptor tyrosine kinase signaling in vascular development. Cell Growth Differ 8: 3-10, 1997.
101. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994.
102. Keyt BA, Nguyen HV, Berleau LT, et al: Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. J Biol Chem 271:5638-5646, 1996.
103. Shalaby F, Rossant J, Yamaguchi TP, et al: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66, 1995.
104. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 11:73-91, 1995.
105. Brekken RA, Huang X, King SW, et al: Vascular epithelial growth factor as a marker of tumor epithelium. Cancer Res 58: 1952-1959, 1998.
106. Millauer B, Longhi MP, Plate KH, et al: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56:1615-1620, 1996.
107. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91, 1995.
108. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599, 1997.
109. Oku T, Tjuvajev JG, Miyagawa T, et al: Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 58:4185-4192, 1998.
110. Zhu Z, Rockwell P, Lu D, et al: Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 58:3209-3214, 1998.
111. Luo JC, Toyoda M, Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58:2594-2600, 1998.
112. Bouvet M, Ellis LM, Nishizaki M, et al: Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58:2288-2292, 1998.
113. Lin P, Sankar S, Shan S-Q, et al: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9:49-58, 1998.
114. Hicklin DJ, Pytowski B, Rockwell P, et al: Monoclonal antivascular endothelial growth factor (VEGF) receptor (KDR) antibodies which are inhibitors of VEGF binding and antagonists of VEGF-stimulated signaling and growth of human endothelial cells. Proc Am Assoc Cancer Res 39:96, 1998.
115. Vajkoczy P, Menger MD, Vollmar B, et al: Effect of the FLK-1 antagonist SU5416 on tumor growth, angiogenesis and microhemodynamics. Proc Am Assoc Cancer Res 39:96, 1998 (abstract).
116. Parry TJ, Bouhana K, Gallegos AM, et al: Antitumor and anti-metastatic efficacy of a ribozyme targeting Flt-1 VEGF receptor mRNA. Proc Am Assoc Cancer Res 39:96, 1998.
117. Wood J, Buchdunger E, Cozens R, et al : Pharmacological profile of a potent and orally active inhibitor of VEGF receptor tyrosine kinases. Proc Am Assoc Cancer Res 39:96-97, 1998.
118. Kamiya K, Konno H, Tanaka T, et al: Antitumor effect of VEGF neutralizing antibody on the human gastric cancer. Induction of apoptosis. Proc Am Assoc Cancer Res 39:44, 1998.
119. Matsumoto K, Konno H, Tanaka T, et al: Antitumor effect of combination treatment with VEGF neutralizing antibody and mitromycin C on the human gastric cancer. Proc Am Assoc Cancer Res 39:44, 1998.
120. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer. Am J Pathol 153:1249-1256, 1998.
121. Im S-A, Gomez-Manzano C, Fueyo J, et al: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59:895-900, 1999.
122. Klagsburn M: Angiogenesis and cancer. Cancer Res 59:487-490, 1999.
123. Nguyen JT, Wu P, Clouse ME, et al: Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 58:5673-5677, 1998.
124. Maglione D, Guerriero V, Viglietto G, et al: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267-9271, 1991.
125. Hauser S, Weich HA: A heparin-binding form of placenta growth factor (PIGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 9:259-268, 1993.
126. Relf M, LeJeune S, Scott PAE, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997.
127. Takahashi A, Sasaki H, Kim SJ, et al: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54:4233-4237, 1994.
128. Viglietto G, Maglione D, Rambaldi M, et al: Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-2579, 1995.
129. Ziehe M, Maglione D, Ribatti D, et al: Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 76:517-531, 1997.
130. Terman BI, Khandke L, Dougher-Vermazan M, et al: VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor. Growth Factors 11:187-195, 1994.
131. Sawano A, Takahashi T, Yamaguchi S, et al: Flt-1 but not KDR/ Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 7:213-221, 1996.
132. Park JE, Chen HH, Winer J, et al: Placenta growth factor. J Biol Chem 269:25646-25654, 1994.
133. Birkenhager R, Schneppe B, Rockl W, et al: Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Biochem J 316:703-707, 1996.
134. Cao Y, Chen H, Zhou L, et al: Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 271: 3154-3162, 1996.
135. DiSalvo J, Bayne ML, Conn G, et al: Purification and characterization of a naturally occurring vascular endothelial growth factor-placenta growth factor heterodimer. J Biol Chem 270:7717-7723, 1995.
136. Grimmond S, Lagercrantz J, Drinkwater C, et al: Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res 6:124-131, 1996.
137. Joukov V, Pajusola K, Kaipainen A, et al: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298, 1996.
138. Lee J, Gray A, Yuan J, et al: Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93:1988-1992, 1996.
139. Olofsson B, Pajusola K, von Euler G, et al: Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem 271:19310-19317, 1996.
140. Olofsson B, Pajulosa K, Kaipainen A, et al: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576-2581, 1996.
141. Yamada Y, Nezu J, Shimane M, et al: Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 42:483-488, 1997.
142. Sowter HM, Corps AN, Evans AL, et al: Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 77:607-614, 1997.
143. Nicosia RF: What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol 153: 11-16, 1998.
144. Kukk E, Lymboussaki A, Taira S, et al: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122:3829-3837, 1996.
145. Lymboussaki A, Partanen TA, Olofsson B, et al: Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol 153:395-403, 1998.
146. Pajusola K, Aprelikova O, Pelicci G, et al: Signaling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene 9:3545-3555, 1994.
147. Joukov V, Sorsa T, Kumar V, et al: Proteolytic processing regulates receptor sensitivity and activity of VEGF-C. EMBO J 16: 3898-3911, 1997.
148. Witzenbichler B, Asahara T, Murohara T, et al: Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 153:381-394, 1998.
149. Achen MG, Jeltsch M, Kukk E, et al: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk 1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548-553, 1998.
150. Salven P, Lymboussaki A, Heikkila P, et al: Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:103-108, 1998.
151. Yamasaki M, Miyake A, Tagashira S, et al: Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family. J Biol Chem 271:15918-15921, 1996.
152. Smallwood PM, Munoz-Sanjuan I, Tong P, et al: Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci USA 93:9850-9857, 1996.
153. Coulier F, Pontarotti P, Roubin R, et al: Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J Mol Evol 44:43-56, 1997.
154. Sato Y, Rifkin DB: Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 107: 1199-1205, 1988.
155. Rifkin DB, Moscatelli D: Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 109:1-6, 1989.
156. Klein S, Giancotti F, Presta M, et al: Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 4:973-982, 1993.
157. Hughes SE, Hall PA: The fibroblast growth factor and receptor multigene families. J Pathol 170:219-221, 1993.
158. Christofori G: The role of fibroblast growth factors in tumour progression and angiogenesis. In: Tumour Angiogenesis, edited by R Bicknell, CE Lewis, N Ferrara, New York, Oxford University Press, 1997, pp. 201-237.
159. Klein S, Roghani M, Rifkin DB: Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. In: Regulation of Angiogenesis, edited by ID Goldberg, EM Rosen, Boston, Birkhauser Verlag, 1997, pp. 159-192.
160. Klagsburn M: Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Semin Cancer Biol 3:81-87, 1992.
161. Taraboletti G, Belotti D, Borsotti P, et al: The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 8:471-479, 1997.
162. Nguyen M, Watanabe H, Budson AE, et al: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer. J Natl Cancer Inst 86:356-361, 1994.
163. Chodak GW, Hospelhorn V, Judge SM, et al: Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 48:2083-2088, 1988.
164. Dinney CPN, Fishbeck R, Singh RK, et al: Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice J Urol 154:1532-1538, 1995.
165. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al: Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85:1597-1599, 1993.
166. Hori A, Sasada R, Matsutani E, et al: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51:6180-6184, 1991.
167. Campbell SC, Volpert OV, Ivanovich M, et al: Molecular mediators of angiogenesis in bladder cancer. Cancer Res 58:1298-1304, 1998.
168. Dinney CPN, Bielenberg DR, Perrotte P, et al: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res 58:808-814, 1998.
169. Kandel J, Bossy-Wetzel E, Radvanyi F, et al: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095-1104, 1991.
170. Anandappa SY, Winstanley JHR, Leinster S, et al: Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer 69:772-776, 1994.
171. Eguchi J, Nomata K, Kanda S, et al: Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinoma. Biochem Biophys Res Commun 183:937-944, 1992.
172. Luqmani YA, Graham M, Coombes RC: Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 66:273-280, 1992.
173. Takahashi JA, Mori H, Fukumoto M, et al: Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 87:5710-5714, 1990.
174. Saksela O, Moscatelli D, Sommer A, et al: Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107:743-751, 1988.
175. Vlodavsky I, Folkman J, Sullivan R, et al: Endothelial cell-derived basic fibroblast growth factors: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84:2292-2296, 1987.
176. Bashkin P, Doctrow S, Klagsburn M, et al: Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28:1737-1743, 1989.
177. O'Brien T, Cranston D, Fuggle S, et al: Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res 57:136-140, 1997.
178. Pepper MS, Ferrara N, Orci L, et al: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824-831, 1992.
179. Goto F, Goto K, Weindel K, et al: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 69:508-517, 1993.
180. Asahara T, Bauters C, Zheng LP, et al: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92 (Suppl II):II-365-II-371, 1995.
181. Montesano R, Vassalli J-D, Baird A, et al: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 83:7297-7301, 1986.
182. Gospodarowicz D, Neufield G, Schweigerer L: Fibroblast growth factor: structural and biological properties. J Cell Physiol Suppl 5:15-26, 1987.
183. Mignatti P, Tsuboi R, Robbins E, et al: In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 108:671-682, 1989.
184. Klagsbrun M, D'Amore PA: Regulators of angiogenesis. Annu Rev Physiol 53:217-239, 1991.
185. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267:10931-10934, 1992.
186. Haimovitz-Friedman A, Balaban N, McLoughlin M, et al: Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54:2591-2597, 1994.
187. Fuks Z, Persaud RS, Alfieri A, et al: Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54:2582-2590, 1994.
188. Miyagawa K, Sakamoto H, Yoshida T, et al: hst-1 transforming protein: expression in silkworm cells and characterization as a novel heparin-binding growth factor. Oncogene 3:383-389, 1988.
189. Yoshida T, Ishimaru K, Sakamoto H, et al: Angiogenic activity of the recombinant hst-1 protein. Cancer Lett 83:261-268, 1994.
190. Pizette S, Batoz M, Prats H, et al: Production and functional characterization of human recombinant FGF-6 protein. Cell Growth Differ 2:561-566, 1991.
191. Beckner ME, Liotta LA: Growth factors and cytokines in tumor invasion and metastasis. In: Growth Factors and Cytokines in Health and Disease, Vol. 3B, edited by D LeRoith, C Bondy, Greenwich, JAI Press, 1997, pp. 381-437.
192. Dimitroff CJ, Klohs W, Sharma A, et al: Evaluation of the effects of PD166285 and PD173074 on in vitro and in vivo angiogenesis. Proc Am Assoc Cancer Res 39:96, 1998 (abstract).
193. Driscoll D, Steinkampf R, Hamby J, et al: Evaluation of tyrosine kinase inhibitors in vitro models of angiogenesis. Proc Am Assoc Cancer Res 39:96, 1998 (abstract).
194. Warren RS, Yuan H, Matli MR, et al: Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271:29483-29488, 1996.
195. Grant M, Jerdan J, Merimee TJ: Insulin-like growth factor-I modulates endothelial cell chemotaxis. J Clin Endocrinol Metab 65:370-371, 1987.
196. Nakao-Hayashi J, Ito H, Kanayasu T, et al: Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 92:141-149, 1992.
197. Rom WN, Basset P, Fells GA, et al: Alveolar macrophages release an insulin-like growth factor 1-type molecule. J Clin Invest 82:1685-1693, 1988.
198. Filkins JP: Endotoxin-enhanced secretion of macrophage insulin-like activity. J Reticuloendothel Soc 27:507-511, 1980.
199. Singer C, Rasmussen A, Smith HS, et al: Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: Evidence for paracrine function. Cancer Res 55: 2448-2454, 1995.
200. Kim K-W, Bae S-K, Lee O-H, et al: Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 58:348-351, 1998.
201. King GL, Goodman D, Buzney S, et al: Receptors and growth promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillary and aorta. J Clin Invest 75: 1028-1036, 1985.
202. Nakamura T, Nishizawa T, Hagiya M, et al: Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443, 1989.
203. Stoker M, Gherardi E, Perryman M, et al: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239-242, 1987.
204. Montesano R, Matsumoto K, Nakamura T, et al: Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67:901-908, 1991.
205. Tsarfaty I, Resau JH, Rulong S, et al: The met proto-oncogene receptor and luman formation. Science 257:1258-1261, 1992.
206. Grant DS, Kleinman HK, Goldberg I, et al: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90: 1937-1941, 1993.
207. Rosen EM, Grant DS, Kleinman HK, et al: Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. In: Cell Behavior: Adhesion and Motility, edited by G Jones, C Wigley, R Warn, Cambridge, The Company of Biologists Limited, 1993, pp. 227-234.
208. Rosen EM, Nigam SK, Goldberg ID: Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 127:1783-1787, 1994.
209. Rosen EM, Goldberg ID: Scatter factor and angiogenesis. Adv Cancer Res 67:257-279, 1995.
210. Lamszus K, Jin L, Fuchs A, et al: Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest 76:339-353, 1997.
211. Zhau H, Pisters L, Hall MC, et al: Biomarkers associated with prostate cancer progression. J Cell Biochem Suppl 19:208-216, 1994.
212. Naidu YM, Rosen EM, Zitnick R, et al: Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc Natl Acad Sci USA 91:5281-5285, 1994.
213. Laterra J, Nam M, Rosen E, et al: Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 76:565-577, 1997.
214. Montesano R, Soriano JV, Malinda KM, et al: Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ 9:355-365, 1998.
215. Fang W, Hartmann N, Chow DT, et al: Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem 267:25880-25897, 1992.
216. Laaroubi K, Delbe J, Vacherot F, et al: Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. Growth Factors 10:89-98, 1994.
217. Schulte AM, Wellstein A: Pleiotrophin and related molecules. In: Tumour Angiogenesis, edited by R Bicknell, CE Lewis, N Ferrara, New York, Oxford University Press, 1997, pp. 273-289.
218. Raulo E, Chernousov MA, Carey DJ, et al: Isolation of a neuronal cell susrface receptor of heparin binding growth-associated molecule (HB-GAM). J Biol Chem 269:12999-13004, 1994.
219. Riegal AT, Wellstein A: The potential role of the heparin-binding growth factor pleiotrophin in breast cancer. Breast Cancer Res Treat 31:309-314, 1994.
220. Czubayko F, Riegel AT, Wellstein A: Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 269:21358-21363, 1994.
221. Tsutsui J-i, Kadomatsu K, Matsubara S, et al: A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 53:1281-1285, 1993.
222. O'Brien T, Cranston D, Fuggle S, et al: The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 56:2515-2518, 1996.
223. Koch AE, Polverini PJ, Kunkel SL, et al: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801, 1992.
224. Strieter RM, Kunkel SL, Elner VM, et al: Interleukin-8 a corneal factor that induces neovascularization. Am J Pathol 141:1279-1284, 1992.
225. Moore BB, Arenberg DA, Strieter RM: The role of CXC chemokines in the regulation of angiogenesis in association with lung cancer. Trends Cardiovasc Med 8:51-58, 1998.
226. Smith DR, Polverini PJ, Kunkel SL, et al: Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 179:1409-1415, 1994.
227. Strieter RM, Polverini PJ, Arenberg DA, et al: Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukocyte Biol 57:752-762, 1995.
228. Arenberg DA, Kunkel SL, Polverini PJ, et al: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97:2792-2802, 1996.
229. Kitadai Y, Haruma K, Sumii K, et al: Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 152:93-100, 1998.
230. Sankar S, Mahooti-Brooks N, Centrella M, et al: Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor β2. J Biol Chem 270:13567-13572, 1995.
231. Shah M, Foreman DM, Ferguson MWJ: Neutralization of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 108:985-1002, 1995.
232. Massague J, Attisano L, Wrana JL: The TGF-β family and its composite receptors. Trends Cell Biol 4:172-176, 1994.
233. Kingsley DM: The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8:133-146, 1994.
234. Wrana JL, Attisano L, Wieser R, et al: Mechanism of activation of the TGF-β receptor. Nature 370:341-347, 1994.
235. Madri JA, Pratt BA, Tucker AM: Phenotypic modulation of endothelial cells by transforming growth factor β depends upon the composition and organization of the extracellular matrix. J Cell Biol 106:1375-1384, 1988.
236. Merwin JR, Anderson JM, Kocher O, et al: Transforming growth factor betal modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J Cell Physiol 142:117-128, 1990.
237. Madri JA, Sankar S: The biphasic effects of transforming growth factors β in angiogenesis. In: Tumour Angiogenesis, edited by R Bicknell, CE Lewis, N Ferrara, New York, Oxford University Press, 1997, pp. 239-249.
238. Xu J, Matsuzaki K, Mckeehan K, et al: Genomic structure and cloned cDNAs predict that four variants in the kinase domain of serine/threonine kinase receptors arise by alternative splicing and poly(A) addition. Proc Natl Acad Sci USA 91:7957-7961, 1994.
239. Antonelli-Orlidge A, Saunders KB, Smith SR, et al: An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86: 4544-4548, 1989.
240. Sato Y, Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during coculture. J Cell Biol 109:309-315, 1989.
241. Schultz-Cherry S, Murphy-Ullrich JE: Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 122:923-932, 1993.
242. Penttinen RP, Kobayashi S, Bornstein P: Transforming growth factor β increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 85:1105-1108, 1988.
243. Bobik A, Agrotis A, Little PJ: Vascular-derived growth factors: potential role in the development of the tumour vasculature. In: Tumour Angiogenesis, edited by R Bicknell, CE Lewis, N Ferrara, New York, Oxford University Press, 1997, pp. 169-184.
244. Falanga V, Qian SW, Danielpour D, et al: Hypoxia upregulates the synthesis of TGF-β1 by human dermal fibroblasts. J Invest Dermatol 97:634-637, 1991.
245. Kim S-J, Park K, Rudkin BB, et al: Nerve growth factor induces transcription of transforming growth factor-β1 through a specific promoter element in PC12 cells. J Biol Chem 269:3739-3744, 1994.
246. Kim S-J, Lee H-D, Robbins PD, et al: Regulation of transforming growth factor β1 gene expression by the product of the retinoblastoma-susceptibility gene. Proc Natl Acad Sci USA 88: 3052-3056, 1991.
247. Lafyatis R, Lechleider R, Kim S-J, et al: Structural and functional characterization of the transforming growth factor β3 promoter. J Biol Chem 265:19128-19136, 1990.
248. Bang Y-J, Kim S-J, Danielpour D, et al: Cyclic AMP induces transforming growth factor β2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc Natl Acad Sci USA 89:3556-3560, 1992.
249. Matsuno F, Haruta Y, Kondo M, et al: Induction of long-lasting complete regression of distinct preformed solid tumors by targeting endoglin of tumor vasculature. Proc Am Assoc Cancer Res 39:97, 1998.
250. Schreiber AB, Winkler ME, Derynck R: Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250-1253, 1986.
251. Madtes DK, Raines EW, Sakariassen KS, et al: Induction of transforming growth factor-α in activated human alveolar macrophages. Cell 53:285-293, 1988.
252. Rappolee DA, Mark D, Banda MJ, et al: Wound macrophages express TGF-α and other growth factors in vivo: analysis by mRNA phenotyping. Science 241:708-712, 1988.
253. Sato Y, Okamura K, Morimoto A, et al: Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 204:223-229, 1993.
254. Beutler B, Cerami A: Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379-385, 1987.
255. Leibovich SJ, Polverini PJ, Shepard HM, et al: Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 329:630-632, 1987.
256. Scannell G, Waxman K, Kaml GJ, et al: Hypoxia induces a human macrophage cell line to release tumor necrosis factor-α and its soluble receptors in vitro. J Surg Res 54:281-285, 1993.
257. Jaattela M: Biologic activities and mechanisms of action of tumor necrosis factor-α/cachectin. Lab Invest 64:724-742, 1991.
258. Klein LM, Lavker RM, Matis WL, et al: Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion. Proc Natl Acad Sci USA 86:8972-8976, 1989.
259. Shalaby MR, Sundan A, Loetscher H, et al: Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med 172:1517-1520, 1990.
260. Fajardo LF, Allison AC: Tumour necrosis factor α and angiogenesis. In: Tumour Angiogenesis, edited by R Bicknell, CE Lewis, N Ferrara, New York, Oxford University Press, 1997, pp. 261-271.
261. Frater-Schroder M, Risau W, Hallmann R, et al: Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 84:5277-5281, 1987.
262. Fajardo LF, Kwan HH, Kowalski J, et al: Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 140:539-544, 1992.
263. van Hinsbergh VWM, van den Berg EA, Fiers W, et al: Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 75:1991-1998, 1990.
264. Okamura K, Sato Y, Matsuda T, et al: Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells. J Biol Chem 266:19162-19165, 1991.
265. Niedbala MJ, Picarella MS: Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by γ-interferon. Blood 79:678-687, 1992.
266. Leibovich SJ, Polverini PJ, Fong TW, et al: Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci USA 91:4190-4194, 1994.
267. Holzman LB, Marks RM, Dixit VM: A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol 10:5830-5838, 1990.
268. Pandey A, Shao H, Marks RM, et al: Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis. Science 268:567-569, 1995.
269. Robaye B, Mosselmans R, Fiers W, et al: Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol 138:447-453, 1991.
270. Schweigerer L, Malerstein B, Gospodarowicz D: Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem Biophys Res Commun 143:997-1004, 1987.
271. Naylor MS, Stamp GWH, Foulkes WD, et al: Tumor necrosis factor and its receptors in human ovarian cancer. J Clin Invest 91:2194-2206, 1993.
272. Pusztai L, Clover LM, Cooper K, et al: Expression of tumour necrosis factor a and its receptors in carcinoma of the breast. Br J Cancer 70:289-292, 1994.
273. Ross R, Glomset J, Kariya B, et al: A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 71:1207-1210, 1974.
274. Barrett TB, Gajdusek CM, Schwartz SM, et al: Expression of the sis gene by endothelial cells in culture and in vivo. Proc Natl Acad Sci USA 81:6772-6774, 1984.
275. Holmgren L, Glaser A, Pfeifer-Ohlsson S, et al: Angiogenesis during human extraembryonic development involves the spatio-temporal control of PDGF ligand and receptor gene expression. Development 113:749-754, 1991.
276. Liaw L, Schwartz SM: Comparison of gene expression in bovine aortic endothelium in vivo versus in vitro. Arterioscler Thromb 13:985-993, 1993.
277. Bagavandoss P, Wilks JW: Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Biophys Res Commun 170:867-872, 1990.
278. Smits A, Hermansson M, Nister M, et al: Rat brain capillary endothelial cells express functional PDGF B-type receptors. Growth Factors 2:1-8, 1989.
279. Anan K, Morisaki T, Katano M, et al: Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 119:333-339, 1996.
280. Gay CG, Winkles JA: Heparin-binding growth factor-1 stimulation of human endothelial cells induces platelet-derived growth factor A-chain gene expression. J Biol Chem 265:3284-3292, 1990.
281. Lauren J, Gunji Y, Alitalo K: Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Pathol 153:1333-1339, 1998.
282. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, et al: Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79:213-223, 1999.
283. Stratmann A, Risau W, Plate KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459-1466, 1998.
284. Suri C, McClain J, Thurston G, et al: Increased vascularization in mice overexpressing angiopoietin-1. Science 282:468-471, 1998.
285. Suri C, Jones PF, Patan S, et al: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180, 1996.
286. Peters KG, Coogan A, Berry D, et al: Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 77:51-56, 1998.
287. Lin P, Polverini P, Dewhirst M, et al: Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100:2072-2078, 1997.
288. Hatva E, Kaipainen A, Jaaskelainen J, et al: Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumours. Am J Pathol 146:368-378, 1995.
289. Kaipainen A, Vlaykova T, Hatva E, et al: Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 54:6571-6577, 1994.
290. Salven P, Joensuu H, Heikkila P, et al: Endothelial tie growth factor receptor provides angiogenic marker for assessment of breast cancer angiogenesis. Br J Cancer 74:69-72, 1996.
291. Ishikawa F, Miyazono K, Hellman U, et al: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557-562, 1989.
292. Miyazono K, Takaku F: Platelet-derived endothelial cell growth factor: structure and function. Jpn Circulation J 55:1022-1026, 1991.
293. Haraguchi M, Miyndera K, Uemura K, et al: Angiogenic activity of enzymes. Nature 368:198, 1994.
294. Moghaddam A, Zhang H-T, Fan T-PD, et al: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:998-1002, 1995.
295. Usuki K, Heldin N-E, Miyazono K, et al: Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture. Proc Natl Acad Sci USA 86:7427-7431, 1989.
296. Yoshimura A, Kuwazuru Y, Furukawa T, et al: Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes, and tumors. Biochim Biophys Acta 1034:107-113, 1990.
297. Reynolds K, Farzaneh F, Collins WP, et al: Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 86:1234-1238, 1994.
298. Moghaddam A, Zhang H-T, Fan T-PD, et al: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:998-1002, 1995.
299. O'Brien T, Cranston D, Fuggle S, et al: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55:510-513, 1995.
300. O'Brien T, Fox SB, Dickinson AJ, et al: Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 56:4799-4804, 1996.
301. Takebayashi Y, Akiyama S-I, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110-1117, 1996.
302. Takahashi Y, Bucana CD, Liu W, et al: Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 88:1146-1151, 1996.
303. Takebayashi Y, Yamada K, Miyadera K, et al: The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A:1227-1232, 1996.
304. Eda H, Fujimoto K, Watanabe S-I, et al: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32:333-338, 1993.
305. Schwartz EL, Wan E, Wang F-S, et al: Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res 58: 1551-1557, 1998.
306. Carmeliet P, Mackman N, Moons L, et al: Role of tissue factor in embryonic blood vessel development. Nature 383:73-75, 1996.
307. Contrino J, Hair G, Kreutzer DL, et al: In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nat Med 2:209-215, 1996.
308. Zhang Y, Deng Y, Luther T, et al: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320-1327, 1994.
309. Shoji M, Abe K, Dillehay D, et al: Tissue factor (TF) regulates the expression of vascular endothelial growth factor (VEGF) in vitro and angiogenesis in vivo in human breast cancer and melanoma. Blood 88:514a, 1996.
310. Shoji M, Abe K, Nawroth PP, et al: Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med 7:52-59, 1997.
311. Folkman J: Tumor angiogenesis and tissue factor. Nat Med 2: 167-168, 1996.
312. Camerer E, Kolsto A-B, Prydz H: Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 81:1-41, 1996.
313. Clauss M, Gerlach M, Gerlach H, et al: Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545, 1990.
314. Huang X, Molema G, King S, et al: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547-550, 1997.
315. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11-25, 1992.
316. Cheresh DA: Integrins: structure, function, and biological properties. Adv Mol Cell Biol 6:225-252, 1993.
317. Meredith JEJ, Fazeli B, Schwartz MA: The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953-961, 1993.
318. Brooks PC, Montgomery AMP, Rosenfield M, et al: Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994.
319. Re F, Zanetti A, Sironi M, et al: Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 127:537-546, 1994.
320. Montgomery AMP, Reisfeld RA, Cheresh DA: Integrin αvβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 91:8856-8860, 1994.
321. Ruoslahti E, Reed JC: Anchorage dependence, integrins, and apoptosis. Cell 77:477-478, 1994.
322. Ruoslahti E: Stretching is good for a cell. Science 276:1345-1346, 1997.
323. Varner JA, Emerson DA, Juliano RL: Integrin α5β1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 6:725-740, 1995.
324. Davis GE, Camarillo CW: Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways. Exp Cell Res 216:113-123, 1995.
325. Friedlander M, Brooks PC, Shaffer RW, et al: Definition of two angiogenic pathways by distinct αv integrins. Science 270: 1500-1502, 1995.
326. Swerlick RA, Brown EJ, Xu Y, et al: Expression and modulation of the vitronectin receptor on human dermal microvascular endothelial cells. J Invest Dermatol 99:715-722, 1992.
327. Enenstein J, Waleh NS, Kramer RH: Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 203:499-503, 1992.
328. Leavesley DI, Schwartz MA, Rosenfeld M, et al: Integrin β1- and β3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 121:163-170, 1993.
329. Healy JM, Murayama O, Maeda T, et al: Peptide ligands for integrin αvβ3 selected from random phage display libraries. Biochemistry 34:3948-3955, 1995.
330. Brooks PC, Clark RAF, Cheresh DA: Requirement of vascular integrin αvβ3 for angiogenesis. Science 264:569-571, 1994.
331. Brooks PC, Stromblad S, Klemke R, et al: Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822, 1995.
332. Mohler T, Brooks PC, Mitjans F, et al: Antagonists of integrin αvβ3/αvβ5: an anti-angiogenic strategy for the treatment of cancer. Proc Am Assoc Cancer Res 39:97, 1998.
333. Nickols A, Carron C, Meyer D, et al: Inhibition of tumor growth and metastasis by an αvβ3 integrin antagonist. Proc Am Assoc Cancer Res 39:97, 1998.
334. Arap W, Pasqualini R, Ruoslahti: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380, 1998.
335. Albelda SM, Oliver PD, Romer LH, et al: EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol 110:1227-1237, 1990.
336. Madri JA, Bell L, Merwin JR: Modulation of vascular cell behavior by transforming growth factors β. Mol Reprod Dev 32: 121-126, 1992.
337. DeLisser HM, Yan HC, Newman PJ, et al: Platelet/endothelial cell adhesion molecule-1(CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans. J Biol Chem 268: 16037-16046, 1993.
338. Piali L, Hammel P, Uherek C, et al: CD31/PECAM-1 is a ligand for αvβ3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol 130:451-460, 1995.
339. DeLisser HM, Christofidou-Solomidou M, Strieter RM, et al: Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151:671-677, 1997.
340. DeLisser HM, Baldwin HS, Albelda SM: Platelet endothelial cell adhesion molecule 1 (PECAM-1/CD31): a multifunctional vascular cell adhesion molecule. Trends Cardiovasc Med 7:203-210, 1997.
341. Kim CS, Wang T, Madri JA: Platelet endothelial cell adhesion molecule-1 expression modulates endothelial migration in vitro. Lab Invest 78:583-590, 1998.
342. Madri JA, Williams SK, Wyatt T, et al: Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 97:153-165, 1983.
343. Basson CT, Knowles WJ, Bell L, et al: Spatiotemporal segration of endothelial cell integrin and nonintegrin extracellular matrix-binding proteins during adhesion events. J Cell Biol 110:789-801, 1990.
344. Chen C, Mrksich M, Huang S, et al: Geometric control of cell life and death. Science 276:1425-1428, 1997.
345. Ingber DE: Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy. Semin Cancer Biol 3:57-63, 1992.
346. Herbst TJ, McCarthy JB, Tsilibary EC, et al: Differential effects of laminin, intact type IV collagen, and specific domains of type IV collagen on endothelial cell adhesion and migration. J Cell Biol 106:1365-1373, 1988.
347. Bowersox JC, Sorgente N: Chemotaxis of aortic endothelial cells in response to fibronectin. Cancer Res 42:2547-2551, 1982.
348. Form DM, Pratt BM, Madri JA: Endothelial cell proliferation during angiogenesis in vitro modulation by basement membrane components. Lab Invest 55:521-530, 1986.
349. Madri JA, Pratt BA: Endothelial cell-matrix interactions: In vitro models of angiogenesis. J Histochem Cytochem 34:85-91, 1986.
350. Kubota Y, Kleinman HK, Martin GR, et al: Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107:1589-1598, 1988.
351. Schnaper HW, Kleinman HK, Grant DS: Role of laminin in endothelial cell recognition and differentiation. Kidney Int 43:20-25, 1993.
352. Kleinman HK, Weeks BS, Schnaper HW, et al: The laminins: a family of basement membrane glycoproteins important in cell differentiation and tumor metastases. Vitam Horm 47:161-186, 1993.
353. Kleinman HK, McGarvey ML, Liotta LA, et al: Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 21: 6188-6193, 1982.
354. Vukicevic S, Kleinman HK, Luyten FP, et al: Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res 202:1-8, 1992.
355. Grant DS, Kleinman HK: Regulation of capillary formation by laminin and other components. In: Regulation of Angiogenesis, edited by ID Goldberg, EM Rosen, Boston, Birkhauser Verlag, 1997, pp. 317-333.
356. Iruela-Arispe ML, Hasselaar P, Sage H: Differential expression of extracellular proteins is correlated with angiogenesis in vitro. Lab Invest 64:174-186, 1991.
357. Iruela-Arispe ML, Diglio CA, Sage EH: Modulation of extracellular matrix proteins by endothelial cells undergoing angiogenesis in vitro. Arteriosclerosis Thromb 11:805-815, 1991.
358. Tokida Y, Aratani Y, Morita A, et al: Production of two variant laminin forms by endothelial cells and shift of their relative levels by angiostatic steroids. J Biol Chem 265:18123-18129, 1990.
359. Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Biol 3:89-96, 1992.
360. Maragoudakis ME, Tsopanoglou N, Haralabopoulos G, et al: Regulation of angiogenesis: the role of protein kinase, nitric oxide, thrombin and basement membrane synthesis. In: Angiogenesis Molecular Biology, Clinical Aspects, Vol. 263, edited by ME, Maragoudakis, PM Gullino, PI Lelkes, New York, Plenum Press, 1994, pp. 125-134.
361. Boehm T, Folkman J, Browder T, et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:335-336, 1997.
362. Dhanabal M, Ramchandran R, Volk R, et al: Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59:189-197, 1999.
363. Zagzag D, Friedlander DR, Miller DC, et al: Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 55: 907-914, 1995.
364. Zagzag D, Friedlander DR, Dosik J, et al: Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 56:182-189, 1996.
365. MacDonald TJ, Laug WE: Migration of human brain tumor cells and human brain endothelial cells on tenascin requires the integrin αvβ3: a unifying model for brain tumor invasion and angiogenesis. Proc Am Assoc Cancer Res 39:497, 1998.
366. r 43,000 glycoprotein ligand. J Cell Physiol 127:373-387, 1986.
367. Sage H, Vernon RB, Deckner J, et al: Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J Histochem Cytochem 37:819-829, 1989.
368. Lane TF, Iruela-Arispe ML, Johnson RS, et al: SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 125:929-943, 1994.
369. 2+-dependent binding to the extracellular matrix. J Cell Biol
370. Gilles C, Bassuk JA, Pulyaeva H, et al: SPARC/Osteonectin induces matrix metallproteinase 2 activation in human breast cancer cell lines. Cancer Res 58:5529-5536, 1998.
371. Beckner ME, Krutzsch HC, Stracke ML, et al: Identification of a new immunoglobulin superfamily protein expressed in blood vessels with a heparin-binding consensus sequence. Cancer Res 55:2140-2149, 1995.
372. Beckner ME, Liotta LA: AAMP, a conserved protein with immunoglobulin and WD40 domains, regulates endothelial tube formation in vitro. Lab Invest 75:97-107, 1996.
373. Beckner ME, Peterson VA, Moul DE: Angio-associated migratory cell protein is expressed as an extracellular protein in vitro by blood vessel-associated mesenchymal cells. Microvasc Res 57:347-352, 1999.
374. Beckner ME, Baylis C, Jagannathan S, et al: Antibody to angioassociated migratory cell protein (anti-rAAMP) inhibits angiogenesis (submitted).
375. Beckner ME, Peterson VA, Todd JH, et al: Angio-associated migratory cell protein is expressed in transformed and malignant human cells. Proc Am Assoc Cancer Res 39:42, 1998.
376. Ropponen K, Tammi M, Parkkinen J, et al: Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58:342-347, 1998.
377. Feinberg RN, Beebe DC: Hyaluronate in vasculogenesis. Science 220:1177-1179, 1983.
378. West DC, Hampson IN, Arnold F, et al: Angiogenesis induced by degradation products of hyaluronic acid. Science 228:1324-1326, 1985.
379. West DC, Kumar S: The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res 183:179-196, 1989.
380. Sattar A, Rooney P, Kumar S, et al: Application of angiogenic oligosaccharides of hyaluronan increases blood vessel numbers in rat skin. J Invest Dermatol 103:576-579, 1994.
381. Montesano R, Kumar S, Orci L, et al: Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. Lab Invest 75:249-262, 1996.
382. Rooney P, Wang M, Kumar P, et al: Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells. J Cell Sci 105:213-218, 1993.
383. Slevin M, Krupinski J, Kumar S, et al: Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. Lab Invest 78:987-1003, 1998.
384. Kumar S, Ponting J, Rooney P, et al: Hyaluronan and angiogenesis: molecular mechanisms and clinical applications. In: Angiogenesis: Molecular Biology, Clinical Aspects, edited by ME Maragoudakis, PM Gullino, PI Lelkes, New York, Plenum Press, 1994, pp. 219-231.
385. Lokeshwar VB, Obek C, Soloway MS, et al: Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 57:773-777, 1997.
386. Halfter W, Dong S, Schurer B, et al: Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 273: 25404-25412, 1998.
387. Bashkin P, Razin E, Eldor A, et al: Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix. Blood 75:2204-2212, 1990.
388. Folkman J, Weisz PB, Joullie MM, et al: Control of angiogenesis with synthetic heparin substitutes. Science 243:1490-1493, 1989.
389. Harris AL, Fox S, Bicknell R, et al: Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer 74:1021-1025, 1994.
390. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997.
391. Aviezer D, Hecht D, Safran M, et al: Perlecan, basai lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79:1005-1013, 1994.
392. Dvorak HF, Dvorak AM, Manseau EJ, et al: Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in Line 1 tumor regression. J Natl Cancer Inst 62:1459-1472, 1979.
393. Dvorak HF, Harvey VS, Estrella P, et al: Fibrin containing gels induce angiogenesis. Lab Invest 57:673-686, 1987.
394. Shoji M, Hancock WW, Abe K, et al: Activation of coagulation and angiogenesis in cancer. Am J Pathol 152:399-411, 1998.
395. Qi J, Kreutzer DL: Fibrin activation of vascular endothelial cells. J Immunol 155:867-876, 1995.
396. Walz DA, Fenton JW: The role of thrombin in tumor cell metastasis. Invasion Metast 14:303-308, 1995.
397. Mignatti P, Rifkin DB: Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49:117-137, 1996.
398. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336, 1991.
399. Pepper MS, Montesano R, Mandriota SJ, et al: Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 49:138-162, 1996.
400. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121-125, 1990.
401. Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 7:147-154, 1996.
402. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195, 1993.
403. Chapman JHA, Stone OL: Co-operation between plasmin and elastase in elastin degradation by intact murine macrophages. Biochem J 222:721-728, 1984.
404. Blei F, Wilson EL, Mignatti P, et al: Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 155:568-578, 1993.
405. Moses MA, Langer R: A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 47:230-235, 1991.
406. Wolff JEA, Guerin C, Laterra J, et al: Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res 604:79-85, 1993.
407. Itoh T, Tanioka M, Yoshida H, et al: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58:1048-1051, 1998.
408. Fibbi G, Caldini R, Chevanne M, et al: Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab Invest 78:1109-1119, 1998.
409. Pollack R, Rifkin D: Actin-containing cables within anchorage-dependent rat embryo cells are dissociated by plasmin and trypsin. Cell 6:495-506, 1975.
410. Pepper MS, Belin D, Montesano R, et al: Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 111:743-755, 1990.
411. Lamoreaux WJ, Fitzgerald MEC, Reiner A, et al: Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55:29-42, 1998.
412. Chen Z-Q, Fisher RJ, Riggs CW, et al: Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. Cancer Res 57:2013-2019, 1997.
413. Rasmussen HS, McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75:69-75, 1997.
414. Chambers AF, Wylie S, MacDonald IC, et al: The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Proc Am Assoc Cancer Res 39:83, 1998.
415. Gopurala B, Siegal GP, Zhang M, et al: A novel synthetic dipeptide inhibits tumor invasion and angiogenesis. Proc Am Assoc Cancer Res 39:44, 1998.
416. Riviere M, Alaoui-Jamali M, Falardeau P, et al: Neovastat: an inhibitor of angiogenesis with anti cancer activity. Proc Am Assoc Cancer Res 39:46, 1998.
417. O'Reilly MS, Holmgren L, Chen C, et al: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692, 1996.
418. Tanaka T, Cao Y, Folkman J, et al: Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 58:3362-3369, 1998.
419. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994.
420. Gorski DH, Mauceri HJ, Salloum RM, et al: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58:5686-5689, 1998.
421. Jendraschak E, Sage EH: Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Semin Cancer Biol 7:139-146, 1996.
422. Folkman J: Angiogenesis and angiogenesis inhibition: an overview. In: Regulation of Angiogenesis, edited by ID Goldberg, EM Rosen, Boston, Birkhauser Verlag, 1997, pp. 1-8.
423. O'Reilly MS: Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. In: Regulation of Angiogenesis, edited by ID Goldberg, EM Rosen, Boston, Birkhauser Verlag, 1997, pp. 273-294.
424. Bachelot T, Pawliuk R, Treilleux I, et al: Retrovirus-mediated gene transfer of an angiostatin-endostatin fusion protein with enhanced anti-tumor properties in vivo. Proc Am Assoc Cancer Res 39:271, 1998.
425. Thomsen L, Lawton FG, Knowles RG, et al: Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54: 1352-1354, 1994.
426. Thomsen LL, Miles DW, Happerfield L, et al: Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41-44, 1995.
427. Cobbs CS, Brennan JE, Aldape KD, et al: Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55:727-730, 1995.
428. Ambs S, Merriam WG, Bennett WP, et al: Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 58:334-341, 1998.
429. Jenkins DC, Charles IG, Thomsen LL, et al: Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92:4392-4396, 1995.
430. Maeda H, Noguchi Y, Sato K, et al: Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 85:331-334, 1994.
431. Tozer GM, Prise VE, Chaplin DJ: Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 57:948-955, 1997.
432. Dimmeler S, Haendeler J, Nehls M, et al: Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 185:601-607, 1997.
433. Tzeng E, Kim Y-M, Pitt BR, et al: Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery 122:255-263, 1997.
434. Murrell GAC, Jang D, Williams RJ: Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 206:15-21, 1995.
435. Rajagopalan S, Meng SP, Ramasamy S. et al: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 98:2572-2579, 1996.
436. Tamura T, Nakanishi T, Kimura Y, et al: Nitric oxide mediates interleukin-1-induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: a possible mechanism of pathological neovascularization in arthritis. Endocrinology 137:3729-3737, 1996.
437. Thomsen LL, Scott JMJ, Topley P, et al: Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res 57:3300-3304, 1997.
438. Melillo G, Musso T, Sica A, et al: A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182:1683-1693, 1995.
439. Ziche M, Morbidelli L, Choudhuri R, et al: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99:2625-2634, 1997.
440. Noiri E, Lee E, Testa J, et al: Podokinesis in endothelial cell migration: role of nitric oxide. Am J Physiol 274:C236-C244, 1998.
441. Babaei S, Teichert-Kuliszewska K, Monge J-C, et al: Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 82:1007-1015, 1998.
442. Ziche M, Morbidelli L, Mantelli L, et al: The proliferative effect of substance P on capillary endothelial cells is mediated by nitric oxide. In: Angiogenesis: Molecular Biology, Clinical Aspects, edited by ME Maragoudakis, PM Gullino, PI Lelkes, New York, Plenum Press, 1994, pp. 91-101.
443. Spisni E, Tomasi V: Involvement of prostanoids in angiogenesis. In: Tumour Angiogenesis, edited by R Bicknell, CE Lewis, N Ferrara, New York, Oxford University Press, 1997, pp. 291-300.
444. Hla T: Early response genes in endothelial cells. In: Angiogenesis: Molecular Biology, Clinical Aspects, Vol. Series A: 263, edited by ME Maragoudakis, PM Gullino, PI Lelkes, New York, Plenum Press, 1994, pp. 67-72.
445. Allison AC, Kowalski WJ: Prostaglandins as transducers of proliferation signals in microvascular endothelial cells and the pharmacological control of angiogenesis. In: Vascular Endothelium Receptors and Transduction Mechanisms, edited by JD Catravas, CN Gillis, US, Ryan, New York, Plenum Press, 1988, pp. 99-110.
446. Smith WL, Meade EA, DeWitt DL:Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann NY Acad Sci 744:50-57, 1994.
447. 1 in osteoblasts. J Clin Invest 93:2490-2496, 1994.
448. 2) synthase is a constitutively expressed enzyme in human endothelial cells. Exp Cell Res 219:507-513, 1995.
449. Pearson JD, May MJ: Regulation of endothelial cell function by cytokines. In: Immunological Aspects of the Vascular Endothelium, edited by COS Savage, JD Pearson, Cambridge, Cambridge University Press, 1995, pp. 20-42.
450. Shaul PW, Campbell WB, Farrar MA, et al: Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase. J Clin Invest 90:2147-2155, 1992.
451. Brannon TS, North AJ, Wells LB, et al: Prostacyclin synthesis in ovine pulmonary artery is developmentally regulated by changes in cyclooxygenase-1 gene expression. J Clin Invest 93: 2230-2235, 1994.
452. Gao X, Grignon DJ, Chbihi T, et al: Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46:227-237, 1995.
453. Tang DG, Renaud C, Stojakovic S, et al: 12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis. Biochem Biophys Res Commun 211:462-468, 1995.
454. Tang DG, Diglio CA, Bazaz R, et al: Transcriptional activation of endothelial cell integrin αv by protein kinase C activator 12(S)-HETE. J Cell Sci 108:2629-2644, 1995.
455. Honn KV, Tang DG, Grossi I, et al: Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Res 54:565-574, 1994.
456. Nie D, Hillman GG, Geddes T, et al: Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 58:4047-4051, 1998.
457. Kinsella JL, Grant DS, Weeks BS, et al. Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel. Exp Cell Res 199:56-62, 1992.
458. Seymour LW, Shoaibi MA, Martin A, et al: Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells. Lab Invest 75:427-437, 1996.
459. Fett JW, Strydom DJ, Lobb RR, et al: Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24:5480-5486, 1985.
460. Weiner HL, Weiner LH, Swain JL: Tissue distribution and developmental expression of the messenger RNA encoding angiogenin. Science 237:280-282, 1987.
461. Jackson D, Volpert OV, Bouck N, et al: Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 266:1581-1584, 1994.
462. Haudenschild CC, Klibaner MI: Nonpeptide angiogenesis factors. In: Angiogenesis Mechanisms and Pathobiology, edited by DB Rifkin, M Klagsburn, Cold Spring Harbor, Cold Spring Harbor Laboratory, 1987, pp. 78-84.
463. Montrucchio G, Sapino A, Bussolati B, et al: Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol 153:1589-1596, 1998.
464. Fenselau A: Tumor and related angiogenesis factors. In: Growth and Maturation Factors, edited by G Guroff, New York, John Wiley & Sons, 1984, pp. 87-129.
465. Vallee BL, Riordan JF, Lobb RR, et al: Tumor-derived angiogenesis factors from rat Walker 256 carcinoma: an experimental investigation and review. Experientia 41:1-15, 1985.
466. Albini A, Benelli R, Presta M, et al: HIBV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 12:289-297, 1996.